Medication Errors Special Interest Group of the International Society of Pharmacovigilance and the Trends in International Collaboration for Patient Safety.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Works matching IS 01145916 AND DT 2022 AND VI 45 AND IP 2
Results: 9
1
2
Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
- Published in:
- Drug Safety, 2022, v. 45, n. 2, p. 169, doi. 10.1007/s40264-021-01142-3
- By:
- Publication type:
- Article
3
Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity.
- Published in:
- Drug Safety, 2022, v. 45, n. 2, p. 137, doi. 10.1007/s40264-021-01138-z
- By:
- Publication type:
- Article
4
Review of Over 15 Years Postmarketing Safety Surveillance Spontaneous Data for the Human Rotavirus Vaccine (Rotarix) on Intussusception.
- Published in:
- Drug Safety, 2022, v. 45, n. 2, p. 155, doi. 10.1007/s40264-021-01141-4
- By:
- Publication type:
- Article
5
Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports.
- Published in:
- Drug Safety, 2022, v. 45, n. 2, p. 145, doi. 10.1007/s40264-021-01139-y
- By:
- Publication type:
- Article
6
β-Blockers and the Risk of Depression: A Matched Case–Control Study.
- Published in:
- Drug Safety, 2022, v. 45, n. 2, p. 181, doi. 10.1007/s40264-021-01140-5
- By:
- Publication type:
- Article
7
Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity.
- Published in:
- Drug Safety, 2022, v. 45, n. 2, p. 101, doi. 10.1007/s40264-021-01132-5
- By:
- Publication type:
- Article
8
Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
9
Use of Identical INN "Imiglucerase" for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database.
- Published in:
- Drug Safety, 2022, v. 45, n. 2, p. 127, doi. 10.1007/s40264-021-01125-4
- By:
- Publication type:
- Article